Biotech Bets: Cardio, Cancer, Vaccines, and Ebola

Jay Silverman is a biotechnology stock analyst and an editor at the industry leading biotech newsletter, The Medical Technology Stock Letter. Here, he offers an in-depth look at three of his favorite biotech stocks.

Steven Halpern: Our guest today is Jay Silverman, a biotech stock analyst with Medical Technology Stock Letter. How are you doing today, Jay?

Jay Silverman: Very well, Steve. Thank you very much.

Steven Halpern: Well, thank you for joining us. We have seen a lot of volatility in the biotech sector. Could you share your general long-term outlook for biotech stocks and, perhaps, highlight some of the catalysts that you foresee impacting the sector?

Jay Silverman: Well, we have been in what we call the golden age of biotech. We have had an accommodative FDA. We have had a bunch of new drug launches that have been highly successful.

We have discovered, and are developing new drugs every day, in a new paradigm for drug discovery, and the big-cap biotech stocks have delivered both in the laboratory and in the earnings front like most people couldn’t imagine just six months ago or a year ago.

Steven Halpern: In the latest issue of the Medical Technology Stock Letter, you state that the market has given investors a tremendous opportunity in one particular company called The Medicines Company (MDCO). In fact, you call it shockingly undervalued. Could you expand on that?

Jay Silverman: Sure, well, The Medicines Company has evolved into an acute care company in the hospital in a number of areas; cardiovascular, infectious disease, and soon to be a pain franchise.